These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7572797)

  • 1. Prevalence and patient profile in activated protein C resistance.
    Samaha M; Trossaert M; Conard J; Horellou MH; Elalamy I; Samama MM
    Am J Clin Pathol; 1995 Oct; 104(4):450-4. PubMed ID: 7572797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial thrombophilia and activated protein C resistance: thrombotic risk in pregnancy?
    Cook G; Walker ID; McCall F; Conkie JA; Greer IA
    Br J Haematol; 1994 Aug; 87(4):873-5. PubMed ID: 7986734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of activated protein C resistance and analysis of clinical profile in thromboembolic patients. A Belgian prospective study.
    Hainaut P; Azerad MA; Lehmann E; Schlit AF; Zech F; Heusterspreute M; Philippe M; Col C; Lavenne E; Moriau M
    J Intern Med; 1997 May; 241(5):427-33. PubMed ID: 9183312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved characteristics of aPC-resistance assay: Coatest aPC resistance by predilution of samples with factor V deficient plasma.
    Kapiotis S; Quehenberger P; Jilma B; Handler S; Pabinger-Fasching I; Mannhalter C; Speiser W
    Am J Clin Pathol; 1996 Nov; 106(5):588-93. PubMed ID: 8929467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects.
    Halbmayer WM; Haushofer A; Schön R; Fischer M
    Blood Coagul Fibrinolysis; 1994 Feb; 5(1):51-7. PubMed ID: 8180338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance to activated protein C as pathogenic factor of venous thromboembolism.
    Chrobák L; Dulícek P
    Acta Medica (Hradec Kralove); 1996; 39(2):55-62. PubMed ID: 9108706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to activated protein C as a basis for venous thrombosis.
    Svensson PJ; Dahlbäck B
    N Engl J Med; 1994 Feb; 330(8):517-22. PubMed ID: 8302317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activated protein C resistance assay as a screening test for thromboembolic disposition.
    Shizuka R; Amagai H; Kojima J; Fukumura Y; Kanda T; Kobayashi I
    J Med; 1997; 28(5-6):381-6. PubMed ID: 9604796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inherited resistance to activated protein C caused by presence of the FV:Q506 allele as a basis of venous thrombosis.
    Dahlbäck B; Zöller B; Hillarp A
    Haemostasis; 1996 Oct; 26 Suppl 4():301-14. PubMed ID: 8979136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombotic tendency in 75 symptomatic, unrelated patients with APC resistance.
    Melichart M; Kyrle PA; Eichinger S; Rintelen C; Mannhalter C; Pabinger I
    Wien Klin Wochenschr; 1996; 108(19):607-10. PubMed ID: 8921576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence and clinical manifestations of activated protein C resistance and factor V Leiden in young patients with venous thromboembolic disease in Spain.
    Olave T; Cornudella R; Homs C; Azaceta G; Tirado I; Gutierrez M
    Haematologica; 1998 Apr; 83(4):378-80. PubMed ID: 9592991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
    Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A
    Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of three reactants for the detection of activated protein C resistance due to mutation of factor V Leiden during pregnancy].
    Magdelaine A; Soubrier F; Berkane N; Uzan S; Verdy E
    Ann Biol Clin (Paris); 1998; 56(4):445-50. PubMed ID: 9754280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to activated protein C: a common inherited cause of venous thrombosis.
    Gillespie DL; Carrington LR; Griffin JH; Alving BM
    Ann Vasc Surg; 1996 Mar; 10(2):174-7. PubMed ID: 8733870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of activated protein C resistance as a potential marker for hypercoagulable state.
    Sakata T; Kario K; Katayama Y; Matsuyama T; Kato H; Miyata T
    Thromb Res; 1996 May; 82(3):235-44. PubMed ID: 8732627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated protein C resistance assay performance: improvement by sample dilution with factor V-deficient plasma.
    Strobl FJ; Hoffman S; Huber S; Williams EC; Voelkerding KV
    Arch Pathol Lab Med; 1998 May; 122(5):430-3. PubMed ID: 9593344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombotic risk factors and oral contraception.
    Bokarewa MI; Falk G; Sten-Linder M; Egberg N; Blombäck M; Bremme K
    J Lab Clin Med; 1995 Sep; 126(3):294-8. PubMed ID: 7665978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
    De Stefano V; Leone G
    Haematologica; 1995; 80(4):344-56. PubMed ID: 7590506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated protein C resistance: prevalence and implications in peripheral vascular disease.
    Ouriel K; Green RM; DeWeese JA; Cimino C
    J Vasc Surg; 1996 Jan; 23(1):46-51, Discussion 51-2. PubMed ID: 8558741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.